Health protection involves the prevention and control of threats to health from communicable diseases and the environment. Health protection is achieved through a complex array of activities involving multiple agencies. Health protection activities include: • immunisation • the provision of safe environments including clean water, food and air • disease surveillance, epidemiological investigations, risk assessments, capacity building, quality assurance, providing expert advice • the development and application of legislation, regulations, policies and guidelines, distributing resources, and monitoring of program performance and outcomes.
In New South Wales (NSW) in 2011, these functions were carried out by a range of groups: at the Ministry of Health the Communicable Diseases Branch, the AIDS/ Infectious Diseases Branch and the Environmental Health Branch; public health units within the local health districts; local government; other government agencies; and the community.
In this report we highlight the major health outcomes and achievements related to the health protection activities of NSW Health in 2011. The health outcomes described in this report are measured mainly through routine surveillance data that are derived from notifications of selected diseases provided by doctors, hospitals and laboratories to public health units under the former NSW Public Health Act 1991.*
The degree to which these notification data reflect the true incidence of disease varies between conditions, as many people with infectious disease will not be diagnosed with the disease or notified to public health units. However for some diseases, such as measles and tuberculosis, where a large proportion of people with the infection develop symptoms, present for health care and undergo confirmatory diagnostic testing soon after symptoms develop, notification data can come close to approximating the incidence of disease. For other conditions, such as hepatitis C, hepatitis B and chlamydia, where many people with the infection do not develop acute symptoms, and many acute infections are not diagnosed, notifications alone cannot be used to approximate the incidence of the disease.
Health outcomes related to environmental hazards (e.g. air pollution, poor water quality and poor housing) are harder to quantify. This is because a single environmental exposure may cause a number of different diseases and these diseases may also be caused by a number of other exposures. For example, particulate air pollution is known to cause heart disease, asthma and lung cancer. However, smoking, a high fat diet, allergies and infections may also cause these diseases. As a consequence, it is rarely possible to relate exposure to environmental hazards directly to health outcomes. Instead, hazards are monitored to identify and manage changes in population exposure. For example, the Environmental Health Branch maintains a comprehensive drinking water quality monitoring system and the NSW Office of Environment and Heritage maintains a network of air quality monitors.
Tables 1-6 summarise disease-specific data on notifiable conditions reported by: year of onset of illness; month of onset of illness; local health district; age group; and sex.
Vaccine-preventable diseases Notification data
In 2011 there were:
• over 13 000 pertussis case notifications, a record number, mostly in 5-9-year old children (over 4000 notifications), followed by 0-4-year old children (over 2400) and 10-14-year olds (over 2300). There was considerable variation in pertussis notification rates between local health districts. The pertussis epidemic highlights the Condition  2002  2003  2004  2005  2006  2007  2008  2009  2010  2011  Total   Adverse event after immunisation  178  219  187  107  72  241  259  126  176  204  1769  Anthrax  0  0  0  0  1  0  0  0  1  0  2  Arboviral infection  659  1020  1140  1078  1918  1499  1848  1411  1556  1171  13 395  412  404  392  366  388  323  329  307  330  3646  Influenza  1010  862  940  1422  681  2061  1867  12856  1601  5625  28 925  Influenza -Type A a  768  769  793  1134  488  1704  841  12580  1415  3955  24 447  Influenza -Type B a  241  55  120  267  183  183  1006  162  143  1566  3926  Influenza -Type A&B a  NN  NN  0  10  2  2  3  12  36  29  94  Influenza -Type NOS a  1  38  27  11  8  172  17  102  7  75  458  Legionellosis  44  60  80  88  78  104  90  94  93  91  822  Legionella longbeachae a  21  37  26  23  22  29  52  64  47  31  352  L. pneumophila a  22  23  52  64  56  73  38  28  38  57  451  Legionnaires' disease -other  1  0  2  1  0  2  0  2  8  3  1 9  Leprosy  0  2  5  1  1  4  4  0  1  2  2 0  Leptospirosis a  39  39  40  35  17  9  17  18  22  39  275  Listeriosis a  11  28  30  25  26  22  34  27  26  21  250  Lymphogranuloma venereum a  0  0  1  2  1  0  3  4  5 6  3 2  5  3  3  1  5  4  3  3  4  3 3  Meningococcal -other  50  46  33  37  29  17  13  20  13  18  276  Meningococcal -conjunctivitis  3  4  3  3  5  3  1  4  2  1  2 9  Mumps a  29  36  65  111  155  323  77  40  39  65  940  Paratyphoid a,c  1 3  2 2  1 0  0  0  0  0  0  0  0  4 5  Pertussis  2014  2771  3567  5800  4914  2099  8757  12 437  9326  13 053  64 738  Pneumococcal disease (invasive) a  881  801  902  641  561  519  548  474  500  524  6351  Psittacosis a  155  88  81  121  94  35  40  22  16  19  671  Q fever a  308  287  220  143  177  205  167  139  137  114  1897  Rotavirus a  NN  NN  NN  NN  NN  NN  NN  NN  1381  1054  2435  Rubella  35  24  18  10  37  9  17  7  13  17  187  Congenital rubella a  0  1  1  0  0  1  0  0  0  0  3  Rubella -other a  35  23  17  10  37  8  17  7  13  17  184  Salmonella infection a,c  2110  1853  2139  2157  2052  2531  2275  2740  3766  3486  25109  Shigellosis a  85  59  96  134  74  71  109  153  116  132  1029  Syphilis  460  785  755  550  617  823  841  936  811  775  7353  Congenital syphilis  2  3  1  1 0  4  5  3  0  0  3  3 1  Syphilis infection a,d  126  242  294  241  230  457  428  529  419  416  3382  Syphilis -other a  332  540  460  299  383  361  410  407  392  356  3940  Tetanus  0  1  1  1  2  2  1  2  1  1  1 2  Tuberculosis a,e  448  388  413  463  454  457  494  513  468  306  4404  Typhoid a  26  15  38  27  35  34  43  47  30  45 Adverse event after immunisation  6  0  1  23  20  3  19  5  43  3  10  5  22  33  11  0  0  0 12  19  56  223  47  131  182  11  32  244  26  22  33  15  113  0  3  2  1171  Barmah Forest virus infections a  0  7  16  76  20  73  51  3  5  152  3  1  18  2  29  0  1  0  457  Ross River virus infections a  3  6  40  129  4  58  129  6  6  86  2  3  11  3  82  0  2  1  571  Other a  9  6  0  18  23  0  2  2  21  6  21  18  4  10  2  0  0  1  143  Blood lead level $15 ug/dl a  11  7  42  11  5  0  62  10  4  0  13  21  4 19 Year in review: health protection in NSW, 2011 These data do not include children who received these free vaccines from general practitioners (GPs) or other immunisation providers.
Initiatives to improve vaccination coverage in 2011 included:
• the introduction into the routine immunisation schedule of a 13-valent conjugate pneumococcal vaccine and implementation of a supplementary dose program for children who had received three doses of the 7-valent vaccine • the continued provision of free pertussis vaccine for new parents, grandparents and other adults who regularly care for infants under 12 months of age, in an effort to indirectly protect those babies in light of the ongoing pertussis epidemic • the development of strategies and health-system capacity to follow-up Aboriginal children who are overdue for vaccination • the provision of free measles-mumps-rubella vaccine to unvaccinated people born in or since 1966 and to contacts of people with measles, to prevent further transmission in the community • working with Divisions of General Practice, local councils and community health centres to improve coverage in areas of low vaccination coverage.
Bloodborne viruses Notification data
In 2011 there was:
• a stable number of total hepatitis B case notifications (n ¼ 2540); 51% were in people aged 25-44 years (total notifications are mainly of people whose time of infection is unknown). However the number of hepatitis B notifications thought to be newly acquired has steadily declined over the last 5 years, from 56 reported in 2007 to 31 in 2011 • a slight decrease in hepatitis C case notifications (3329 notifications, down from 3816 in 2010). Case-patients were most commonly men aged 25-44 years (33%), men aged 45-64 years (24%) and women aged 25-44 years (18%). The number of notifications of newly acquired hepatitis C infections remained stable (n ¼ 44, compared with 39 in 2010; the annual average over the previous 5 years is 45) • a slight increase in case notifications of human immunodeficiency virus (HIV) with 330 reported in 2011 (compared to 307 in 2010). The age groups most affected were those aged 30-39 years (n ¼ 123; 37%) and 20-29 years (n ¼ 90; 27%). In 2011, 277 notifications (84%) were reported to be homosexually acquired.
Improvements in methods for data cleaning have identified duplicate notifications for hepatitis B and C cases, resulting in a more accurate count of cases and a reduction in the overall number of notifications for previous years, particularly for before 2005.
Prevention activities NSW Health has a range of policies and strategies in place to control the spread of HIV, hepatitis B and hepatitis C, including regular campaigns to promote safer sex, needle and syringe programs to provide sterile equipment to injecting drug users, and support of the management of patients with sexually transmissible infections and hepatitis C. Highlights in 2011 included:
• ACON (formerly the AIDS Council of NSW) developed an HIV prevention campaign for gay men called The Big Picture (www.hivthebigpicture.org.au), designed to inform gay men in NSW about the risks for HIV transmission. It also offered the gay community strategies for keeping infection rates low: maintain condom use, increase HIV testing, encourage the disclosure of HIV status and restrict sex without condoms to men of the same HIV status • the NSW Expanded Medication Access Scheme for HIV Section 100 drugs (Highly Specialised Drugs Program) to provide people with HIV with improved access to treatment in NSW. This scheme was developed in light of both long-standing and recent evidence of the effectiveness of HIV antiretroviral therapy in preventing the sexual transmission of HIV. 1 Under the new Scheme, patients who are stable on their medications and meet certain criteria can elect to have their medication delivered to any address of their choosing rather than attend a hospital pharmacy. A number of select retail pharmacies also operate as pick up locations for patients • NSW publicly funded HIV and sexual health clinics provided 79 046 occasions of services to 6536 clients related to HIV treatment, management and care (an increase of 2.2% of occasions of services and 1.0% of clients compared with 2010) • the first phase of a hepatitis C prevention campaign, aiming to increase awareness of the transmission and prevention of hepatitis C for young people. Brochures and posters were distributed to 750 general practices in NSW. In 2010/11, the NSW Needle and Syringe Program comprised over 940 outlets (332 public sector outlets, 159 dispensing machines and 450 pharmacies) • Approximately 9.98 million needles and syringes were dispensed and over 13 400 referrals were provided to drug treatment services, hepatitis services and other health and welfare agencies for people who inject drugs • 3014 patients with hepatitis C were referred for hepatitis C assessment, 1062 patients initiated treatment and 989 patients completed treatment.
Sexually transmissible infections Notification data
• a similar number of infectious syphilis case notifications compared with recent years (416, compared with 419 in 2010, and a 5-year average of 412) • a decrease in the number of lymphogranuloma venereum (LGV) case notifications (39, compared with 56 in 2010). All notifications were reported in males, and 37 (95%) case-patients were aged between 25 and 64 years. The number of notifications decreased in late 2010 following an outbreak earlier in that year. The outbreak in NSW occurred within the global context of increased European rates of LGV infection in men who have sex with men 2 • a continued increase in the number of chlamydia case notifications (20 536, up 13% from 18 254 in 2010); 57% of cases notified were female and 59% of cases were aged between 15 and 24 years • an increase in the number of gonorrhoea notifications (2879, up 26% from 2301 in 2010). Men made up 80% of cases and 54% of these case-patients were aged 25-44 years.
Overall, notifications of sexually transmissible infections (STIs) in NSW continue to rise with chlamydia continuing to be the most commonly notified STI in NSW. Much of the increase in chlamydia and at least some of the increase in gonorrhoea notifications may relate to increased screening and case detection.
Prevention activities
Highlights in 2011 included:
• the NSW STIs in Gay Men Action Group (STIGMA) (a partnership of state and local prevention agencies based in central and south eastern Sydney) developed While there is no local transmission of dengue fever in NSW, it is the most common mosquitoborne viral disease in humans worldwide, and represents a major international public health concern • a 38% decrease in the number of malaria case notifications (76, compared with 122 in 2010). Travel to Papua New Guinea was the most commonly reported exposure site (25%), followed by India (13%) and Ghana (11%).
The NSW arbovirus surveillance program includes: mosquito trapping and the monitoring of virus activity in mosquito populations; and, monitoring for antibodies to Murray Valley encephalitis and Kunjin virus infection in sentinel chicken flocks located in a number of strategic sites in rural NSW from mid-spring to mid-autumn when transmission of arbovirus infections is most common.
With increasing international travel, exotic mosquitoborne diseases such as dengue fever, malaria and chikungunya will pose an ongoing risk for people travelling to endemic areas. International trade also increases the risk of the importation of exotic mosquito species which are able to transmit these infections locally. Aboriginal Communities Water and Sewerage Program Clean water and functioning sewerage systems are a prerequisite for good health. Widespread availability of these essential services improves health by reducing communicable diseases such as skin infections and diarrhoeal illness. The Aboriginal Communities Water and Sewerage Program is a joint partnership between the NSW Government and the NSW Aboriginal Land Council. 9 The Program aims to ensure adequate operation, maintenance and monitoring of water supplies and sewerage systems in more than 60 Aboriginal communities in NSW. NSW Health is involved in the development and implementation of the Program. The program is now being expanded in partnerships with Local Government to increase Aboriginality in the overall NSW environmental health workforce (much of which is based in Local Government) • four new trainee positions were created under funding agreements between the Aboriginal Environmental Health Unit, regional public health units and Local Governments.
Negotiations are in place for further Local Government trainee positions which will start during 2012.
